Semaine's evidence hub for Urinary Tract Cleanse & Protect. Includes our own consumer study data and the published peer-reviewed literature on the Anthocran® Phytosome® ingredient. All sources linked; study designs stated honestly.
Overview
Most urinary supplements point you to "cranberry research" in general. We can do something more specific: Urinary Tract Cleanse & Protect uses Anthocran® Phytosome®, the exact cranberry phytosome ingredient studied in the published literature below — and we ran our own consumer study on the finished product. This page lays out both, with study designs labeled plainly so you can judge the strength of each.
There are four questions the evidence answers:
- Do the compounds reach the urinary tract and act there? (mechanism)
- Does the right delivery form change clinical outcomes? (RCT)
- Does it hold up in high-risk groups? (registry / population studies)
- What do women using the finished product report over time? (our consumer study)
1. Our consumer perception study (the finished product)
Design (stated plainly): a third-party-conducted consumer perception study — not a placebo-controlled clinical trial and not registered on ClinicalTrials.gov. n=48 women, age 40+, five-month use period. Participants self-reported change across urinary and adjacent measures at five monthly time points (M1–M5). Results reflect what women reported over time.
Percent of participants reporting improvement, by month:
| Measure (as surveyed) | M1 | M2 | M3 | M4 | M5 |
|---|---|---|---|---|---|
| Bladder irritation | 63.9% | 83.3% | 83.3% | 88.9% | 80.6% |
| Urinary comfort (burning when urinating) | 68.6% | 74.3% | 77.1% | 82.9% | 85.7% |
| Nighttime urination | 46.3% | 58.5% | 78.0% | 80.5% | 78.0% |
| Urine leakage | 57.5% | 72.5% | 75.0% | 75.0% | 62.5% |
| Urinary environment (smelly/cloudy urine) | 57.9% | 68.4% | 68.4% | 89.5% | 84.2% |
| Pelvic comfort | 61.1% | 66.7% | 72.2% | 77.8% | 75.0% |
| Vaginal environment | 65.7% | 82.9% | 77.1% | 85.7% | 77.1% |
| Intimacy comfort | 63.2% | 78.9% | 81.6% | 78.9% | 73.7% |
| Sexual comfort | 56.8% | 75.7% | 67.6% | 75.7% | 75.7% |
How to read this honestly: these are perceptions, not microbiologically confirmed outcomes, in a small uncontrolled sample. The most defensible pattern is the trajectory — most measures build over the first several months and hold, consistent with daily, cumulative support rather than an instant fix. We report M5 as the study endpoint (we don't cherry-pick the M4 peak). The measures with the cleanest sustained improvement through M5 are urinary comfort, nighttime urination, pelvic comfort, and sexual comfort.
2. Mechanism: do the compounds reach the urinary tract?
Baron et al., 2019, Biochemical Pharmacology (DOI, PMID 31778647). After people ingested Anthocran®, researchers identified 42 cranberry-derived compounds and metabolites in human urine — including valerolactones not previously described. Urine fractions collected 12 hours after dosing significantly reduced biofilm formation by a biofilm-forming organism, Candida albicans (p<0.05); the effect was reproduced with the Phytosome™ form and with pure standards. This is the ingestion-to-urine-to-activity bridge.
Ottaviano et al., 2021, Microorganisms (DOI, PMID 34361928). Identified two specific cranberry urinary metabolites (a valerolactone and 4-hydroxybenzoic acid) that drive the anti-biofilm effect in vitro.
de Llano et al., 2015, Int J Mol Sci (DOI, PMID 26023719). Cranberry phenolic metabolites reduced uropathogenic E. coli adhesion to human bladder cells, dose-dependently.
Howell et al., 2010, BMC Infectious Diseases (DOI, PMID 20398248). Anti-adhesion activity in human urine was dose-dependent, with protection up to 24 hours at 72 mg PACs/day.
3. Clinical outcomes: the randomized trial
Rondanelli et al., 2024, Nutrients (DOI, PMID 38999860). A double-blind RCT (46 completers) of 120 mg/day standardized cranberry phytosome vs placebo found a significant time×supplementation effect (p=0.001) on urinary tract episodes — in diabetic postmenopausal women taking SGLT-2 inhibitors, a group at substantially elevated urinary risk. No change in glycemic markers; good safety. The high-risk population makes the signal more, not less, notable.
4. High-risk population: post-catheterization
Cotellese et al., 2021, Journal of Dietary Supplements (DOI, PMID 34632933). A pilot registry of 64 post-surgical/catheterized patients found cranberry phytosome (120–240 mg/day) reduced symptoms, hematuria, and bacterial contamination; none in the cranberry group had a recurrence over the following 3 months (p<0.05).
5. Where the broader cranberry field stands (for honesty)
We don't cherry-pick. The wider cranberry literature is genuinely mixed, mostly because of dose and delivery differences: a meta-analysis found a 26% reduction in recurrence risk (Fu et al., 2017), while a large JAMA trial in nursing-home women found no benefit (Juthani-Mehta et al., 2016), and a high-dose PAC trial missed its primary endpoint (Babar et al., 2021). Our read: the form that has been measured reaching the urine and acting there is the one worth using.
The bottom line
The evidence for Anthocran® Phytosome® is unusually complete for a supplement ingredient: a mechanism showing the compounds arrive in urine and act, a randomized controlled trial in a high-risk population, supporting registry data, and our own multi-month consumer study on the finished product. None of it claims to treat an active infection. All of it supports the same idea: daily support for a healthy urinary environment, using a cranberry form that actually absorbs.
Study designs are stated as conducted. The consumer perception study is observational and self-reported. Published references are peer-reviewed and indexed on PubMed. Educational content; not medical advice.